May 12, 2007 Summary by Dr. Ragiab Ayad, Germany
Fifty five percent reduction of lung cancer risk by using of statin for more than six months as reported in the chest. Statins are commonly used cholesterol-lowering agents that are noted to suppress tumor cell growth in several in vitro and animal models, some authors wrote that to date there is no effective chemopreventive agent identified as a means to reduce the incidence of lung cancer. The association of lung cancer and the use of statins in 483,733 patients from 8 south central states from 1998 to 2004, were studied. Of total patients 34% were receiving statins and 1.5 % had a primary diagnosis of lung cancer. Statin use for more than 6 months was associated with a reduced risk for lung cancer of 55% (OR, 0.45; 95% CI, 0.42 - 0.48; P < .01). The protective effect of statins occurred in different age and racial groups, independent of the presence of smoking status, alcohol use or diabetes. Statins appear to be protective against the development of lung cancer, and further studies need to be done to define the clinical utility of statins as chemoprotective agents. The study recommended that a well-designed randomised prospective double-blinded placebo controlled clinical trials are necessary to validate the value of statins in lung cancer prevention and treatment.
Source:
Vikas Khurana, Hanmanth R. Bejjanki, Gloria Caldito, and Michael W. Owens
Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans. Chest, May 2007; 131: 1282 - 1288.